Revolutionary artificial intelligence applications transform endocrine disease detection and management Attendees at ENDO 2025 in San Francisco were all buzzing about the Elangovan family of Houston, Texas. That’s because high school-aged siblings, Ramya and Kavin, were presenting their research into how artificial intelligence (AI) could change the way certain endocrine disorders were diagnosed and treated....
Newly elected to the Endocrine Society’s Board of Directors on the heels of being named the scientific director of the Division of Translational Toxicology at NIEHS, Heather Patisaul, PhD, talks about how her belief that human advancement and a healthy ecosystem can exist at the same time led to her pioneering work in endocrine-disrupting chemicals....
New research challenges traditional approaches to male reproductive aging One of the posters presented as part of ENDO 2025’s Reproductive Endocrinology tract gained a lot of attention because it shed light on a heretofore unheralded link between men’s sexual well-being and metabolic health. Lead author Michael Zitzmann, MD, PhD, talks to Endocrine News about his...
U.S. FDA Approves Hydrocortisone Oral Solution for Pediatric Adrenocortical Insufficiency
The U.S. Food and Drug Administration (FDA) recently granted a New Drug Application (NDA) for a hydrocortisone oral solution Eton Pharmaceuticals, Inc. is marketing as KHINDIVI™ — a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml...
Rare Pediatric Case of Bilateral Adrenal Leiomyomas Highlights Diagnostic Challenges
“Bilateral Adrenal Leiomyomas in a Pediatric Patient,” a recently published case in JCEM Case Reports describes a highly unusual diagnosis in an 11-year-old boy: bilateral adrenal leiomyomas. These benign smooth muscle tumors are rare in any age group and typically occur unilaterally. The pediatric presentation, particularly affecting both adrenal glands, adds to the clinical rarity...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * New Study Shows that Ozempic® Reduces the Risk of Heart Attack, Stroke, and Death by 23% Compared to Dulaglutide On September 18, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was...
Getting to the Heart of the Matter: GLP-1’s Role in Cardiorespiratory Fitness
Glucagon-like peptide-1 receptor agonists (GLP‑1 Ras) — such as semaglutide and liraglutide — are celebrated for producing weight-loss results comparable to bariatric surgery, improving glucose control, and reducing cardiovascular risk. Yet new questions are surfacing about what users may be losing, besides fat. A recent narrative review in the Journal of Clinical Endocrinology & Metabolism warns...
GLP-1 Agonists and Muscle Loss: A Hidden Risk for Older Adults
As glucagon-like peptide-1 receptor agonists (GLP-1 RAs) — such as semaglutide (Ozempic, Wegovy) — gain traction for treating diabetes and promoting weight loss, a new concern is emerging: Are older adults at risk of losing too much muscle? An editorial in Annals of Internal Medicine warns that these popular drugs may exacerbate sarcopenia — the...
